[Mechanism of Action] Shaperon's Inflammasome Inhibitors
2023-02-10
659
Novel mechanism of Shaperon's inflammasome inhibitors:
Unlike other inflammasome inhibitors which target to inhibit only the activation phase of inflammasome, Shaperon's GPCR19-P2X7 modulation yields multiple advantages over conventional approaches.
Suppresses both priming and activation phase of inflammasome pathway, resulting in the suppression of multiple cytokines and chemokines including ll-1β, TNF-α, IL-6, IL-18, etc.
Acts selectively on inflammatory immune cells
Efficacy variation less likely (GPCR19 is non-polymorphic)
Targeting GPCR19, top regulator of inflammasome activation, avoids NLRP3-associated redundant pathways such as NLRP1, NLRC4, AIM2